# Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

> **NCT03811002** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 544 (actual)

## Conditions studied

- Limited Stage Lung Small Cell Carcinoma
- Stage I Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage III Lung Cancer AJCC v8

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **DRUG:** Atezolizumab
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03811002
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-26
- **Primary completion:** 2024-04-21
- **Final completion:** 2029-02-21
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811002, "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03811002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*